top of page
The Professional Network for Healthcare Experts
Valerio Therapeutics agrees €30 million Etherna acquisition alongside €40.25 million financing
The transaction combines Valerio’s targeted delivery technologies with Etherna’s mRNA, lipid nanoparticle and GMP manufacturing capabilities to build an integrated targeted RNA therapeutics platform.
nuaxia
Aug 263 min read
HanchorBio partners with Taiwan Cancer Moonshot team to advance precision immunotherapy development
The collaboration combines HanchorBio's immuno-oncology platform with Taiwan's national precision oncology programme to support biomarker-driven clinical development and translational research.
nuaxia
Aug 132 min read
FDA grants accelerated approval to Tudriqev for PD-1-refractory advanced melanoma
The engineered oncolytic viral therapy, used with nivolumab, provides a new treatment option for adults with unresectable cutaneous melanoma that has progressed despite prior PD-1-based immunotherapy.
nuaxia
Aug 72 min read
bottom of page